3/5
07:56 am
ikt
Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
Medium
Report
Inhibikase Therapeutics (IKT) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
3/4
08:00 am
ikt
Inhibikase Therapeutics (IKT) is now covered by LADENBURG THALM/SH SH. They set a "buy" rating and a $4.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics (IKT) is now covered by LADENBURG THALM/SH SH. They set a "buy" rating and a $4.00 price target on the stock.
2/25
06:24 am
ikt
Inhibikase Therapeutics (IKT) was upgraded by Lifesci Capital to "strong-buy".
Medium
Report
Inhibikase Therapeutics (IKT) was upgraded by Lifesci Capital to "strong-buy".
1/24
05:08 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Inhibikase Therapeutics (NASDAQ:IKT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
09:00 am
ikt
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $6.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $6.00 price target on the stock.
12/29
02:02 pm
ikt
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/27
08:02 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
12/27
01:05 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at
Wall Str
Low
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at
Wall Str
12/26
08:02 am
ikt
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Inhibikase Therapeutics (NYSE:IKT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/13
07:50 am
ikt
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Medium
Report
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
12/11
08:43 am
ikt
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.